CJC-1295 vs Semax
A comprehensive, data-driven comparison of CJC-1295 (Modified GRF 1-29) and Semax. Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | CJC-1295 Modified GRF 1-29, DAC:GRF | Semax |
|---|---|---|
| FDA Status | Category 2 (pending reclassification) | Not submitted |
| Category | Growth Hormone | Cognitive Enhancement |
| Primary Use | Growth hormone optimization and anti-aging | Cognitive enhancement and neuroprotection |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $35 - $70/mo | $45 - $90/mo |
| Administration | Subcutaneous injection | Nasal spray |
| Typical Dose | 1-2mg twice weekly (with DAC) | 2-3 drops per nostril 2-3x daily |
| Frequency | Twice weekly | Daily |
| Mechanism | Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce more growth hormone | Synthetic ACTH analog that enhances BDNF production, improves cerebral circulation, and protects neurons |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | Emerging | Moderate |
| Clinical Trial Phase | N/A | N/A |
Key Differences
- 1CJC-1295 is generally more affordable ($35 - $70/mo) compared to Semax ($45 - $90/mo).
- 2CJC-1295 is administered via subcutaneous injection, while Semax uses nasal spray.
- 3CJC-1295 is dosed twice weekly, while Semax is daily.
- 4Semax has moderate-quality evidence, while CJC-1295 has emerging-quality evidence.
- 5They belong to different categories: CJC-1295 (Growth Hormone) vs Semax (Cognitive Enhancement).
Which Is Better For...
CJC-1295
More budget-friendly option with lower monthly costs
CJC-1295
More convenient dosing schedule (twice weekly)
Semax
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| CJC-1295 | $35 - $70/mo | Category 2 (pending reclassification) | Various research labs |
| Semax | $45 - $90/mo | Not submitted | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
CJC-1295 works via Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce. Semax works via Synthetic ACTH analog that enhances BDNF production, improves cerebral circulation, and protects. They differ in FDA approval status, efficacy data, and cost.
CJC-1295 typically costs $35 - $70/mo, while Semax costs $45 - $90/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
CJC-1295 is not FDA-approved (Category 2 (pending reclassification)). Semax is not FDA-approved (Not submitted). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of CJC-1295 include Injection site reactions, Water retention, Numbness or tingling. Common side effects of Semax include Nasal irritation, Mild stimulation, Headache. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone. It exists in two forms: with DAC (Drug Affinity Complex) for ex...
View Full CJC-1295 GuideSemax is a synthetic peptide analog of adrenocorticotropic hormone (ACTH) developed in Russia. It has been shown to increase brain-derived neurotrophic factor (BDNF), improve cerebral blood flow, and ...
View Full Semax GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between CJC-1295 and Semax should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.